Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
Werte in diesem Artikel
Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market lately. That is because the Sept 19, 2025 $125.00 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.What do the Analysts Think?Clearly, options traders are pricing in a big move for Alnylam Pharmaceuticals share, but what is the fundamental picture for the company? Currently, Alnylam Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics Industry that ranks in the Top 29% of our Zacks Industry Rank. Over the last 60 days, eight analysts have increased their estimates for the current quarter, while none have revised their estimates downwards. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from 40 cents per share to $1.26 per share in the same time period.Given the way analysts feel about Alnylam Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.Click to see the trades now >>Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Alnylam Pharmaceuticals und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Alnylam Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Alnylam Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Alnylam Pharmaceuticals Inc.
Analysen zu Alnylam Pharmaceuticals Inc.
Datum | Rating | Analyst | |
---|---|---|---|
01.10.2018 | Alnylam Pharmaceuticals Overweight | Cantor Fitzgerald | |
13.08.2018 | Alnylam Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
07.08.2018 | Alnylam Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
05.07.2018 | Alnylam Pharmaceuticals Buy | Chardan Capital Markets | |
04.05.2018 | Alnylam Pharmaceuticals Hold | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
01.10.2018 | Alnylam Pharmaceuticals Overweight | Cantor Fitzgerald | |
13.08.2018 | Alnylam Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
07.08.2018 | Alnylam Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
05.07.2018 | Alnylam Pharmaceuticals Buy | Chardan Capital Markets | |
04.05.2018 | Alnylam Pharmaceuticals Hold | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
30.03.2017 | Alnylam Pharmaceuticals Neutral | UBS AG | |
24.11.2009 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
26.02.2009 | Alnylam Pharmaceuticals Upgrade | Needham & Company, LLC | |
25.02.2009 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
15.09.2008 | Alnylam Pharmaceuticals Ersteinschätzung | Thomas Weisel Partners LLC |
Datum | Rating | Analyst | |
---|---|---|---|
20.08.2008 | Alnylam Pharmaceuticals Ersteinschätzung | Leerink Swann LLC | |
03.03.2008 | Alnylam Pharmaceuticals Downgrade | Needham & Company, LLC |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Alnylam Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen